Testing A New Experimental Drug To Raise Good Cholesterol Level

Testing A New Experimental Drug To Raise Good Cholesterol Level.
An conjectural poison that raises HDL, or "good," cholesterol seems to have passed an sign hurdle by proving safe in preliminary trials. Although the trial was primarily designed to overlook at safety, researchers scheduled to present the finding Wednesday at the American Heart Association's annual assignation in Chicago also report that anacetrapib raised HDL cholesterol by 138 percent and slap in the face LDL, HDL's evil twin, almost in half. "We saw very encouraging reductions in clinical events," said Dr Christopher Cannon, assume command author of the study, which also appears in the Nov 18, 2010 exit of the New England Journal of Medicine.

A big study to seal the results would take four to five years to complete so the drug is still years away from market who is a cardiologist with Brigham and Women's Hospital in Boston. Other experts are intrigued by the findings, but note that the check out is still in very ahead stages. "There are a lot of people in the prevention/lipid field that are simultaneously excited and leery," said Dr Howard Weintraub, clinical concert-master of the Center for the Prevention of Cardiovascular Disease at NYU Langone Medical Center in New York City.

Added Dr John C LaRosa, president of the State University of New York (SUNY) Downstate Medical Center in New York City: "It's very prodromic but it's material because the final drug out of the barrel of this type was not a success. This looks match a better drug, but it's not definitive by any means. Don't take this to the bank".

LaRosa was referring to torcetrapib, which, get off on anacetrapib, belongs to the class of drugs known as cholesterol ester take protein (CETP) inhibitors. A large trial on torcetrapib was killed after investigators found an increased jeopardy of death and other cardiovascular outcomes. "I would be more excited about anacetrapib if I hadn't seen what happened to its cousin torcetrapib. Torcetrapib raised HDL astoundingly but that was completely neutralized by the development in cardiovascular events".